Social Anxiety Disorder

Abstract

<div style="left: 70.8662px; top: 324.72px; font-size: 15.45px; font-family: serif; transform: scaleX(0.971046);" data-canvas-width="419.81549999999993">According to epidemiological studies, rates of social anxiety disorder</div><div style="left: 70.8662px; top: 344.72px; font-size: 15.45px; font-family: serif; transform: scaleX(1.11655);" data-canvas-width="424.26750000000004">(SAD) or social phobia range from 3% to 16% in the general</div><div style="left: 70.8662px; top: 364.72px; font-size: 15.45px; font-family: serif; transform: scaleX(0.987995);" data-canvas-width="69.1185">population.</div><div style="left: 139.985px; top: 365.947px; font-size: 9.00733px; font-family: serif; transform: scaleX(0.952064);" data-canvas-width="16.423109999999998">[1,2]</div><div style="left: 156.408px; top: 364.72px; font-size: 15.45px; font-family: serif; transform: scaleX(0.977187);" data-canvas-width="334.422">Social phobia and specific phobias have an earlier age</div>of onset than other anxiety disorders.

The definition of treatment resistance in anxiety disorders: a Delphi method‐based consensus guideline

“…A prerequisite for conducting these clinical trials and mechanistic studies is an international consensus on the definition of TR‐AD, which is currently lacking 17,26 . International guidelines focusing on anxiety disorders do not provide explicit criteria aiding in the identification or treatment of patients with TR‐AD 15,27‐50 , with only two exceptions. First, the Canadian Clinical Practice Guidelines for the Management of Anxiety Disorders 51 suggest that patients who “do not respond to first‐ or second‐line agents” (in panic disorder), who “do not respond to several medication trials and/or CBT” (in social anxiety disorder), or who “do not respond to multiple courses of therapy” (in GAD) should be considered treatment‐refractory.…”